latest news releases from the newsroom
BioXell Initiates Phase II Clinical Trial with BXL-628 in Benign Prostatic Hyperplasia
MILAN, Italy, March 27, 2003 (PRIMEZONE) -- BioXell SpA, the Italian biopharmaceutical company, today announced that it has initiated recruitment for the Phase II trial of its novel lead compound, BXL-628, in Benign Prostatic Hyperplasia (BPH).The trial, a double-blind, randomised, placebo-controlled study involving 120 patients, will be coordinated by the Division of Urology, Universita Vita e Salute-San Raffaele, Milan and involve 12 centres across Italy.
Allgon Appointed as PDH Microwave Supplier to Marconi
TABY, Sweden, March 27, 2003 (PRIMEZONE) -- Allgon (Other OTC:ALGBF), a global supplier of radio-based infrastructure solutions, has signed a worldwide supply agreement with Marconi Communications GmbH for the supply of Plesiochronous Digital Hierarchy (PDH) Microwave equipment to complement Marconi's range of Fixed Wireless communications solutions.
Kari Lotsberg and Torkel Segerstedt-Nominated for Board of NeoNet
STOCKHOLM, Sweden, March 27, 2003 (PRIMEZONE) -- NeoNet, an international agency broker providing efficient electronic equity execution services for the institutional investor industry, today announced Kari Lotsberg and Torkel Segerstedt to be nominated as members of the Board of Directors of NeoNet AB. They will be nominated as members of the board together with the current board members at the Annual General Meeting 7 May.
New Organization at Saab Aerospace in Linkoping
LINKOPING, Sweden, March 27, 2003 (PRIMEZONE) -- Saab Aerospace in Linkoping, will be given a new organization from July 14, 2003. There will be two new business units: Saab Aerosystems and Saab Aerostructures. In addition, a support organization, Saab Support, will be formed. All units will report directly to Saab's group management.
Abbott Laboratories and Karo Bio Identify Novel new Compound for Diabetes
HUDDINGE, Sweden, March 27, 2003 (PRIMEZONE) -- Abbott Laboratories and Karo Bio AB (Other OTC:KARBF) today announced that they have identified a novel, first-in-class compound, A-348441, for the treatment of type 2 diabetes. Currently in preclinical study, A-348441 targets the glucocorticoid receptor in the liver, which is considered to be an important target protein for regulating glucose metabolism.